STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications
Retrieved on:
Monday, October 10, 2022
Quality of life, Medicine, Asiapac Books, Autism spectrum, Growth, Schizophrenia, ASD, EVG, Glioma, NDD, Neurodevelopmental disorder, Patient, Drug development, AIM, Orphan drug, Precision medicine, Lists of diseases, Company, Disorder, Mike Evgen, Safety, London, Psychiatry, FDA, DEPI, London Stock Exchange, Pharmaceutical industry, Medical device
GENEVA, Oct. 10, 2022 /PRNewswire/ -- STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).
Key Points:
- Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs.
- DEPI has already reached validation through the clinical identification of biologically defined subgroups of patients with ASD, and their respective candidate treatments.
- SFX-01 will strengthen STALICLA's pipeline to advance precision medicine for a new subgroup of patient with Autism Spectrum Disorder.
- Thanks to DEPI, STALICLA identified SFX-01 as the best treatment candidate for its second subgroup of patients, ASD-Phenotype 2.